| Customization: | Available |
|---|---|
| CAS No.: | Customs, Customs |
| Formula: | Customs, Customs |
|
Still deciding? Get samples of US$ 150/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Dacomitinib is a small molecule kinase inhibitor used in the field of oncology. Dacomitinib is orally administered and works by blocking the signals that promote cancer cell growth and division.
Dacomitinib functions as a potent and selective inhibitor of EGFR tyrosine kinase, which plays a crucial role in the development and progression of various cancers, especially non-small cell lung cancer (NSCLC). By inhibiting EGFR, Dacomitinib helps to suppress tumor growth and metastasis, ultimately improving patient outcomes.
ApplicationDacomitinib finds application in the treatment of advanced or metastatic NSCLC with EGFR gene mutations. It is indicated for patients who have failed prior chemotherapy or have not responded to other EGFR inhibitors. Dacomitinib offers potential benefits in terms of improved progression-free survival and overall survival compared to conventional chemotherapy, making it an important therapeutic option for patients with EGFR-mutated NSCLC.
){kind=link}